#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
nstruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Troendle August J.</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Medpace Holdings, Inc. [ MEDP ]									k all app Dired	olicable) ctor		Owner		
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC. 5375 MEDPACE WAY				09/	3. Date of Earliest Transaction (Month/Day/Year) 09/19/2018								X	X Officer (give title Other (specify below)  President & CEO					
(Street)	NATI (	DН	4	5227		4. If	Amer	idment,	Date o	of Origir	nal File	ed (Month/Da	iy/Year)		6. Indi Line) X	Forn	n filed by One	o Filing (Checle e Reporting Per re than One R	erson
(City)	(	State)		Zip)		<u> </u>										_			
			Table	e I - No			_				d, Di	sposed o							
			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			and 5) Secu Bend Own		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership			
							Code	v	Amount	(A) or (D) Price				action(s) 3 and 4)		(Instr. 4)			
Common Stock 09/19/				09/19/2	018				S <sup>(1)</sup>		61,141 <sup>(1)</sup>	D	\$6	0.2 <sup>(2)</sup>	9,0	84,369	I	By Medpace Investors, LLC <sup>(3)</sup>	
Common Stock 09/20				09/20/2	018			S <sup>(1)</sup>		53,842(1)	D	\$58	\$58.29 <sup>(4)</sup>		30,527	I	By Medpace Investors, LLC <sup>(3)</sup>		
Common Stock														35	51,851	D			
Common Stock														1	0,000	I	By Son		
			Ta	ble II -								osed of, convertib				wned			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  Execution Date if any (Month/Day/Year)		med on Date, Day/Year)	4. Transa	ransaction code (Instr. ) Secu Acqu (A) or Dispc of (D) (Instr and 5		mber ative rities ired osed	_	Exerc tion Da l/Day/Y	cisable and ate Amount of Securities Underlying Derivative Security (Inst and 4)  Expiration  7. Title and Amount of Securities Underlying Derivative Amount of Numb of		and It of ties ying tive ty (Instr.	8. P Der Sec (Ins	rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D) or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)			

# **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$58.00 to \$64.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$58.00 to \$58.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

# Remarks:

/s/ Stephen P. Ewald, Attorney-09/21/2018 in-Fact for August J. Troendle

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.